1. NMSIS - Neuroleptic Malignant Syndrome Information Service NMSIS is a resource for initiatives surrounding NMS and other heatrelated disorders. http://www.nmsis.org/

What is NMS What is NMSIS Research Criteria FAQ ... New Section! Other Heat-Related Disorders Featuring Serotonin Syndrome New Section! List of Drugs Associated With NMS New Donor Section! Honor Roll of Donor Listings Thank you from NMSIS New Article! Treating persistent catatonia when benzodiazepines fail? Promising New Investigators awards presented to two winners at the American Psychiatric Association convention in Atlanta, GA on May 22, 2005 Full Report NMS Patient Brochures A brochure for patients, families and caregivers Order your FREE copy! View Word Document Welcome to the Neuroleptic Malignant Syndrome Information Service (NMSIS) NMSIS is a not-for-profit organization founded in 1997 by the Malignant Hyperthermia Association of the United States (MHAUS) in collaboration with a group of prominent experts in psychiatry and psychopharmacology. The mission of NMSIS is to serve as an international resource center for educational and research initiatives to promote awareness, improve patient safety, and reduce morbidity and mortality in relation to heat-related disorders. These conditions are uncommon and may be unfamiliar to most practitioners, but can be encountered during the course of routine clinical practice in psychiatry and medicine.

2. Neuroleptic Malignant Syndrome Clinical features, the pathophysiology and treatment. http://www.cmdg.org/Movement_/drug/Neuroleptic_Malignant_Syndrome/neuroleptic_ma

Drug Induced Movement Disorders NEUROLEPTIC MALIGNANT SYNDROME Clinical Neuroleptic malignant syndrome is the rarest of the neuroleptic induced movement disorders. It is the most serious and represents a neurologic emergency in most cases. It has now been reported to occur with all drugs that effect the central dopaminergic system (including dopamine agonists and levodopa). There's an isolated report of neuroleptic malignant syndrome in a patient on a trycyclic medication. It is likely an idiosyncratic reaction and patients can, if needed, be given the same agent again without recurrence. It is estimated that 0.5-1% of patients exposed to neuroleptics will develop this syndrome. Most patients will develop it shortly after initial exposure and 90% within two weeks of starting the neuroleptic. It can occur with all the neuroleptics but haldol and trifluperazine are the most common. It has also been seen with clozapine and metoclopramide. Physical exhaustion, dehydration, hyponatremia, young male gender, affective disorders, thyrotoxicosis, or prior brain pathology all increase the rate of this syndrome developing. An increased risk occurs in patients combining haldol with lithium.

3. EMedicine - Neuroleptic Malignant Syndrome : Article By Theodore Benzer, MD, PhD An in depth look at neuroleptic malignant syndrome beginning with an introduction.Authored by Theodore Benzer MD. http://www.emedicine.com/emerg/topic339.htm

(advertisement) Home Specialties Resource Centers CME ... Patient Education Articles Images CME Advanced Search Consumer Health Link to this site Back to: eMedicine Specialties Emergency Medicine Toxicology Neuroleptic Malignant Syndrome Last Updated: April 21, 2005 Rate this Article Email to a Colleague Synonyms and related keywords: NMS , idiosyncratic reaction, muscular rigidity, autonomic dysfunction, haloperidol fluphenazine antipsychotic agents , prochlorperazine, promethazine , clozapine, risperidone , metoclopramide, amoxapine lithium , dopamine D2-receptor antagonist, withdrawal of anti-Parkinson medication, respiratory failure cardiovascular collapse myoglobinuric renal failure arrhythmias ... hyperthermia , profuse diaphoresis, sialorrhea metabolic acidosis , dopamine receptor blockade, impaired temperature regulation AUTHOR INFORMATION Section 1 of 10 Author Information Introduction Clinical Differentials ... Bibliography Author: Theodore Benzer, MD, PhD , Chief of Clinical Operations, Chief of Toxicology, Instructor, Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School Theodore Benzer, MD, PhD, is a member of the following medical societies:

4. NORD - National Organization For Rare Disorders, Inc. Offers synonyms, a general discussion and further resources. http://www.rarediseases.org/search/rdbdetail_abstract.html?disname=Neuroleptic M

5. NMSIS - Neuroleptic Malignant Syndrome Information Service Order your FREE copy! View Word Document. Welcome to the neuroleptic malignant syndrome Information Service (NMSIS). http://tmsyn.wc.ask.com/r?t=an&s=hb&uid=24312681243126812&sid=343126

6. NMSIS - Neuroleptic Malignant Syndrome Information Service NMSIS is a resource for initiatives surrounding NMS and other heatrelated disorders. http://www.nmsis.org/general_information.shtml

What is NMS What is NMSIS Research Criteria FAQ ... Disorders NEUROLEPTIC MALIGNANT SYNDROME Stanley N. Caroff, M.D., Professor of Psychiatry Read Dr. Caroff's article in Current Psychiatry Stephan C. Mann, M.D. E. Cabrina Campbell, M.D., Assistant Professor of Psychiatry Department of Veterans Affairs Medical Center, Philadelphia, Pennsylvania Summary Since the initial description of neuroleptic malignant syndrome (NMS) forty years ago, a wealth of clinical data has accumulated on the manifestations, course, treatment and pathogenesis of this uncommon but serious and potentially lethal drug reaction. Nevertheless, vigilance must be maintained, as this disorder remains obscure to most practicing physicians. Herein, the authors provide a clinical overview of NMS to enhance patient safety and reduce physician liability whenever neuroleptics are administered. Introduction Neuroleptic malignant syndrome (NMS) was first described by Delay et al during early trials of haloperidol.

7. NMSIS - Neuroleptic Malignant Syndrome Information Service neuroleptic malignant syndrome. Stanley N. Caroff, M.D., Professor of Psychiatry Read Dr. Caroff's article in Current Psychiatry http://tmsyn.wc.ask.com/r?t=an&s=hb&uid=24312681243126812&sid=343126

8. Virtual Hospital Clinical Psychopharmacology Seminar Serotonin neuroleptic malignant syndrome Includes an introduction, the etiology, clinical features, complications, incidence, risk factors and treatment. http://tmsyn.wc.ask.com/r?t=an&s=hb&uid=24312681243126812&sid=343126

9. EMedicine - Neuroleptic Malignant Syndrome : Article By Darius P Sholevar, MD neuroleptic malignant syndrome neuroleptic malignant syndrome (NMS) refers tothe combination of hyperthermia, rigidity, and autonomic dysregulation that http://www.emedicine.com/med/topic2614.htm

(advertisement) Home Specialties Resource Centers CME ... Patient Education Articles Images CME Patient Education Advanced Search Consumer Health Link to this site Back to: eMedicine Specialties Medicine, Ob/Gyn, Psychiatry, and Surgery Psychiatry Neuroleptic Malignant Syndrome Last Updated: November 6, 2002 Rate this Article Email to a Colleague Synonyms and related keywords: NMS, drug-induced movement disorder, lethal catatonia, neuroleptic-induced acute dystonia, neuroleptic-induced akathisia, neuroleptic-induced parkinsonism, neuroleptic-induced tardive dyskinesia, serotonin syndrome, hyperthermia, rigidity, autonomic dysregulation, 3,4-methylenedioxymethamphetamine, MDMA, ecstasy, XTC AUTHOR INFORMATION Section 1 of 10 Author Information Introduction Clinical Differentials ... Bibliography Author: Darius P Sholevar, MD , Fellow, Cardiovascular Disease, Albert Einstein Medical Center Coauthor(s): Ellen H Sholevar, MD , Director of Child and Adolescent Psychiatry, Associate Professor, Department of Psychiatry, Temple University School of Medicine Editor(s): Alan D Schmetzer, MD

10. NINDS Forwarding Page Compiled by the National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/health_and_medical/disorders/neuroleptic_syndrome.htm

NINDS has redesigned its website and the URL for the page you were seeking has changed. The new URL for this page is /disorders/neuroleptic_syndrome/neuroleptic_syndrome.htm . Please update your bookmark to this page. You will be automatically taken to this page in 5 seconds, or you can click the link to go there now.

11. Neuroleptic Malignant Syndrome Information Page National neuroleptic malignant syndrome information sheet compiled by the National Institute of Neurological Disorders and Stroke (NINDS). http://tmsyn.wc.ask.com/r?t=an&s=hb&uid=24312681243126812&sid=343126

12. NEUROLEPTIC MALIGNANT SYNDROME neuroleptic malignant syndrome OR NMS. This catastrophic reaction to dopamine blocking agents, especially HALDOL, more recently RESPIRADOL, (but all http://tmsyn.wc.ask.com/r?t=an&s=hb&uid=24312681243126812&sid=343126

13. Neuroleptic Malignant Syndrome Information Page: National Institute Of Neurologi neuroleptic malignant syndrome information sheet compiled by the National Instituteof Neurological Disorders and Stroke (NINDS). http://www.ninds.nih.gov/disorders/neuroleptic_syndrome/neuroleptic_syndrome.htm

Accessible version Science for the Brain The nation's leading supporter of biomedical research on disorders of the brain and nervous system More about Neuroleptic Malignant Syndrome Studies with patients Research literature Press releases Search NINDS... (help) Contact Us My Privacy NINDS is part of the National Institutes of Health You are here: Home Disorders Neuroleptic Malignant Syndrome NINDS Neuroleptic Malignant Syndrome Information Page Get Web page suited for printing Email this to a friend or colleague Table of Contents (click to jump to sections) What is Neuroleptic Malignant Syndrome? Is there any treatment? What is the prognosis? What research is being done? ... Organizations What is Neuroleptic Malignant Syndrome? Neuroleptic malignant syndrome is a life-threatening, neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. Symptoms include high fever, sweating, unstable blood pressure, stupor, muscular rigidity, and autonomic dysfunction. In most cases, the disorder develops within the first 2 weeks of treatment with the drug; however, the disorder may develop any time during the therapy period. The syndrome can also occur in people taking anti-Parkinsonism drugs known as dopaminergics if those drugs are discontinued abruptly. Is there any treatment?

14. Welcome! - Malignant Hyperthermia Association Of The United States neuroleptic malignant syndrome Information Service. North American MH Registry of MHAUS. Log In MHAUS Associates Only. My eShop Cart http://tmsyn.wc.ask.com/r?t=an&s=hb&uid=24312681243126812&sid=343126

15. Virtual Hospital: Clinical Psychopharmacology Seminar : Serotonin Syndrome And N Serotonin Syndrome and neuroleptic malignant syndrome (1989) The associationbetween the neuroleptic malignant syndrome and malignant hyperthermia. http://www.vh.org/adult/provider/psychiatry/CPS/09.html

Clinical Psychopharmacology Seminar Serotonin Syndrome and Neuroleptic Malignant Syndrome Original Author: Paul Perry, Ph.D, BCPP Latest Reviser: Vicki Ellingrod, Pharm.D. and Janice Worsham, Pharm.D. Creation Date: 1996 Last Revision Date: June 2005 Peer Review Status: Internally Peer Reviewed INTRODUCTION Both Serotonin Syndrome (SS) and Neuroleptic Malignant Syndrome (NMS) are rare, but potentially life-threatening toxic effects of psychotropic drugs. SS is associated with an excess of serotonin (5HT) usually resulting from increasing the dose of a single serotonergic agonist drug, polypharmacy of serotonic agents, or a pharmacodynamic drug interaction of a monoamine oxidase inhibitor (MAOI) with a serotonin reuptake inhibitor (SRI) (Ciraulo and Shader, 1990). NMS has been associated with antipsychotic (neuroleptic) drugs and other drugs that affect dopamine (DA) neurotransmission. NMS was first described during early studies of haloperidol in 1960 (Delay et al, 1960). The first report of NMS in English literature was in 1968 (Delay and Deniker, 1968). Since NMS occurs very infrequently, it is extremely difficult to characterize it objectively under controlled conditions. As a result, many uncontrolled reports have been published, sometimes with misleading results. Numerous reviews have been published that provide comprehensive discussions of NMS (Caroff and Mann, 1993; Dickey, 1991; Ebadi et al, 1990; Heiman-Patterson, 1993). This review will attempt to compare and contrast the well-established features of NMS and SS. Signs and symptoms common to the two syndromes include excitement, diaphoresis, rigidity, hyperthermia, tachycardia, and hypertension. Depending on the circumstances of the case involved, the washout period between use of an MAOI and an SRI may range from one to more than five weeks. It is during this washout period that a misdiagnosis of NMS would be most likely, particularly when a patient is seeing more than one physician and complete records are not available.

16. Virtual Hospital: Clinical Psychopharmacology Seminar : Serotonin Syndrome And N neuroleptic malignant syndrome Includes an introduction, the etiology, clinical features, complications, incidence, risk factors and treatment. http://www.vh.org/Providers/Conferences/CPS/09.html

Clinical Psychopharmacology Seminar Serotonin Syndrome and Neuroleptic Malignant Syndrome Original Author: Paul Perry, Ph.D, BCPP Latest Reviser: Vicki Ellingrod, Pharm.D. and Janice Worsham, Pharm.D. Creation Date: 1996 Last Revision Date: June 2005 Peer Review Status: Internally Peer Reviewed INTRODUCTION Both Serotonin Syndrome (SS) and Neuroleptic Malignant Syndrome (NMS) are rare, but potentially life-threatening toxic effects of psychotropic drugs. SS is associated with an excess of serotonin (5HT) usually resulting from increasing the dose of a single serotonergic agonist drug, polypharmacy of serotonic agents, or a pharmacodynamic drug interaction of a monoamine oxidase inhibitor (MAOI) with a serotonin reuptake inhibitor (SRI) (Ciraulo and Shader, 1990). NMS has been associated with antipsychotic (neuroleptic) drugs and other drugs that affect dopamine (DA) neurotransmission. NMS was first described during early studies of haloperidol in 1960 (Delay et al, 1960). The first report of NMS in English literature was in 1968 (Delay and Deniker, 1968). Since NMS occurs very infrequently, it is extremely difficult to characterize it objectively under controlled conditions. As a result, many uncontrolled reports have been published, sometimes with misleading results. Numerous reviews have been published that provide comprehensive discussions of NMS (Caroff and Mann, 1993; Dickey, 1991; Ebadi et al, 1990; Heiman-Patterson, 1993). This review will attempt to compare and contrast the well-established features of NMS and SS. Signs and symptoms common to the two syndromes include excitement, diaphoresis, rigidity, hyperthermia, tachycardia, and hypertension. Depending on the circumstances of the case involved, the washout period between use of an MAOI and an SRI may range from one to more than five weeks. It is during this washout period that a misdiagnosis of NMS would be most likely, particularly when a patient is seeing more than one physician and complete records are not available.

17. Jazz, Schizophrenia And Side Effects - Forbes.com Then, ten years ago, the drug caused a deadly condition called neuroleptic malignant syndrome, in which the muscles become rigid, blood http://tmsyn.wc.ask.com/r?t=an&s=hb&uid=24312681243126812&sid=343126

18. Virtual Hospital: Department Of Psychiatry: Psychiatric Emergencies neuroleptic malignant syndrome This is an idiosyncratic reaction to presumablydue to acute dopamine blockade. Risk Factors http://www.vh.org/adult/provider/emergencymedicine/Psychiatry/MedEmergNMS.html

Psychiatric Emergencies Medical Emergencies in Psychiatry Gerard Clancy, M.D. Peer Review Status: Internally Peer Reviewed 2. Neuroleptic Malignant Syndrome This is an idiosyncratic reaction to presumably due to acute dopamine blockade. Risk Factors Males, high environmental temperatures, high potency antipsychotics, start up of antipsychotics or recent increase in dose of antipsychotics, concurrent lithium treatment, dehydration, preexisting medical/neurologic illness, affective illness. Sewell DD, Jeste DV, chapter 12, Medical Psychiatric Practice, Vol I APPI 1991. Signs and Symptoms: Fever, rigidity, diaphoresis, dysphagia, labile blood pressure, Increased pulse rate, altered mental state - delirium. Increased white blood count, increased CPK, SGOT and LDH. Mortality reported from 5 to 20 %. Rhabdomyolysis-> Acute Renal Failure Thrombosis> Pulmonary Embolis Onset is relatively sudden hours to days, which helps distinguish NMS from Lethal Catatonia. Treatment: Obtain medical consultation due to high mortality. Discontinue the antipsychotic immediately.

19. Sympathoadrenal Hyperactivity And The Etiology Of Neuroleptic Sympathoadrenal Hyperactivity and the Etiology of neuroleptic malignant syndrome Ronald J. Gurrera, M.D. http://tmsyn.wc.ask.com/r?t=an&s=hb&uid=24312681243126812&sid=343126

20. Introduction: Neuroleptic Malignant Syndrome - WrongDiagnosis.com Introduction to neuroleptic malignant syndrome as a medical condition includingsymptoms, diagnosis, misdiagnosis, treatment, prevention, and prognosis. http://www.wrongdiagnosis.com/n/neuroleptic_malignant_syndrome/intro.htm

Home Symptoms Diseases Risks ... Diseases Search our medical database Subscribe to our free Newsletter sample Send this page to a friend Condition Lists By Organ By Symptom By Class By Prevalence ... List A-Z Current chapter: Neuroleptic Malignant Syndrome Next sections Basic Summary for Neuroleptic Malignant Syndrome Prognosis of Neuroleptic Malignant Syndrome Symptoms of Neuroleptic Malignant Syndrome Misdiagnosis of Medication Causes of Neuroleptic Malignant Syndrome ... Treatments for Neuroleptic Malignant Syndrome Next chapters: Schizencephaly Niemann-Pick disease Occipital Neuralgia Chronic pain ... Feedback Introduction: Neuroleptic Malignant Syndrome Neuroleptic Malignant Syndrome: Dangerous neurological reaction often from medications. Neuroleptic Malignant Syndrome: Neuroleptic malignant syndrome is a life-threatening, neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs. Researching symptoms of Neuroleptic Malignant Syndrome: Further information about the symptoms of Neuroleptic Malignant Syndrome is available including a list of symptoms of Neuroleptic Malignant Syndrome , or alternatively return to research other symptoms in the symptom center Treatments for Neuroleptic Malignant Syndrome: Various information is available about treatments available for Neuroleptic Malignant Syndrome , or research treatments for other diseases.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 1     1-20 of 104    1  | 2  | 3  | 4  | 5  | 6  | Next 20